| oxaliplatin / Generic mfg. |
NCT00061815: Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer |
|
|
| Completed | 3 | 102 | US | cetuximab, Erbitux™, oxaliplatin, Eloxatin®, leucovorin, Wellcovorin®, 5-fluorouracil, 5-FU | Eli Lilly and Company, Bristol-Myers Squibb | Colorectal Cancer | 12/04 | 11/05 | | |
NCT00077233: FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum |
|
|
| Terminated | 3 | 238 | US | cetuximab, C225, 5-FU, 5-fluorouracil, irinotecan, CPT-11, leucovorin, calcium folinate, oxaliplatin, Eloxatin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Bristol-Myers Squibb, Eli Lilly and Company | Colorectal Cancer | 12/06 | 06/10 | | |
|
|
NCT00056446: Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer |
|
|
| Completed | 3 | 855 | US, Canada, Europe, RoW | Vatalanib, PTK787/ZK 222584 | Novartis Pharmaceuticals, Bayer | Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms | 01/07 | 01/07 | | |
|
| Completed | 3 | 383 | US | gemcitabine/Eloxatin (GEMOX), carboplatin/paclitaxel (CP) | Sanofi | Carcinoma, Non-Small-Cell Lung | 05/07 | | | |
NCT00012389: Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 3 | | US, Canada, Europe, RoW | irinotecan hydrochloride, oxaliplatin | Sanofi | Colorectal Cancer | | 10/08 | | |
NCT00208546: Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer |
|
|
| Completed | 3 | 750 | Europe | 21Capecitabine + bevacizumab + oxaliplatin, 1Capecitabine + oxaliplatin + bevacizumab + cetuximab | Dutch Colorectal Cancer Group, Koningin Wilhelmina Fonds, Sanofi, Roche Pharma AG, Immunicon | Colorectal Cancer | 07/09 | 12/09 | | |
|
|
|
|
NCT00305188 / 2005-002570-30: Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. |
|
|
| Completed | 3 | 879 | US, Canada, Europe, RoW | Xaliproden (SR57746A), Placebo, Oxaliplatin, 5-Fluorouracil, 5-FU, Leucovorin, LV | Sanofi | Metastases, Colorectal Neoplasms, Colorectal Carcinoma | 10/09 | 10/09 | | |
NCT00471965: Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients |
|
|
| Completed | 3 | 371 | RoW | Oxaliplatin + 5-Fluorouracil/Leucovorin, Doxorubicin | Sanofi | Carcinoma, Hepatocellular | 03/10 | 03/10 | | |
AVANT, NCT00112918: Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer |
|
|
| Completed | 3 | 3451 | US | Bevacizumab, Capecitabine, Xeloda®, 5-Fluorouracil (5-FU), Leucovorin calcium, Oxaliplatin | Hoffmann-La Roche, National Cancer Institute (NCI) | Colorectal Cancer | 06/10 | 06/12 | | |
|
SECOX, NCT01245582: Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients |
|
|
| Withdrawn | 3 | 0 | RoW | oxaliplatin (SR96669), capecitabine, sorafenib | Sanofi | Hepatic Neoplasm Malignant | 02/14 | 08/15 | | |
NCT01824459: S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients |
|
|
| Completed | 3 | 576 | RoW | S-1, Oxaliplatin, Cisplatin | Sun Yat-sen University, Taiho Pharmaceutical Co., Ltd. | Gastric Cancer | 12/18 | 12/18 | | |
FAST, NCT00735241: FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma |
|
|
| Withdrawn | 2/3 | 0 | US | SIR-Spheres microspheres, FOLFOX6 cycles 1-3, Eloxatin, Folinic acid, 5-FU, FOLFOX6 cycles 4 onwards, Bevacizumab cycles 3 onwards, Avastin | Sirtex Medical | Colorectal Carcinoma, Liver Metastases | 03/09 | 03/09 | | |
